Cancer mortality following treatment for adult hyperthyroidism

被引:251
作者
Ron, E [1 ]
Doddy, MM
Becker, DV
Brill, AB
Curtis, RE
Goldman, MB
Harris, BSH
Hoffman, DA
McConahey, WM
Maxon, HR
Preston-Martin, S
Warshauer, ME
Wong, FL
Boice, JD
机构
[1] NCI, Radiat Epidemiol Branch, NIH, Bethesda, MD 20892 USA
[2] Cornell Univ, Med Ctr, New York Hosp, New York, NY 10021 USA
[3] Vanderbilt Univ, Nashville, TN USA
[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[5] Res Triangle Inst, Res Triangle Pk, NC 27709 USA
[6] George Washington Univ, Washington, DC 20052 USA
[7] Mayo Clin, Rochester, MN USA
[8] Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA
[9] Univ So Calif, Los Angeles, CA 90089 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1998年 / 280卷 / 04期
关键词
D O I
10.1001/jama.280.4.347
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context.-High-dose iodine 131 is the treatment of choice in the United States for most adults with hyperthyroid disease. Although there is little evidence to link therapeutic I-131 to the development of cancer, its extensive medical use indicates the need for additional evaluation. Objective.-To evaluate cancer mortality among hyperthyroid patients, particularly after I-131 treatment. Design.-A retrospective cohort study. Setting.-Twenty-five clinics in the United States and 1 clinic in England. Patients.-A total of 35 593 hyperthyroid patients treated between 1946 and 1964 in the original Cooperative Thyrotoxicosis Therapy Follow-up Study; 91% had Graves disease, 79% were female, and 65% were treated with I-131. Main Outcome Measure.-Standardized cancer mortality ratios (SMRs) after 3 treatment modalities for hyperthyroidism. Results.-Of the study cohort, 50.5% had died by the end of follow-up in December 1990. The total number of cancer deaths was close to that expected based on mortality rates in the general population (2950 vs 2857.6), but there was a small excess of mortality from cancers of the lung, breast, kidney, and thyroid, and a deficit of deaths from cancers of the uterus and the prostate gland. Patients with toxic nodular goiter had an SMR of 1.16 (95% confidence interval [CI], 1.03-1.30). More than 1 year after treatment, an increased risk of cancer mortality was seen among patients treated exclusively with antithyroid drugs (SMR, 1.31; 95% CI, 1.06-1.60). Radioactive iodine was not linked to total cancer deaths (SMR, 1.02; 95% CI, 0.98-1.07) or to any specific cancer with the exception of thyroid cancer (SMR, 3.94; 95% CI, 2.52-5.86). Conclusions.-Neither hyperthyroidism nor I-131 treatment resulted in a significantly increased risk of total cancer mortality. While there was an elevated risk of thyroid cancer mortality following I-131 treatment, in absolute terms the excess number of deaths was small, and the underlying thyroid disease appeared to play a role. Overall, I-131 appears to be a safe therapy for hyperthyroidism.
引用
收藏
页码:347 / 355
页数:9
相关论文
共 40 条
[11]  
GOLDMAN MB, 1990, CANCER RES, V50, P2283
[12]   RADIOACTIVE IODINE THERAPY AND BREAST-CANCER - A FOLLOW-UP-STUDY OF HYPERTHYROID WOMEN [J].
GOLDMAN, MB ;
MALOOF, F ;
MONSON, RR ;
ASCHENGRAU, A ;
COOPER, DS ;
RIDGWAY, EC .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1988, 127 (05) :969-980
[13]   RADIOIODINE TREATMENT OF GRAVES-DISEASE - AN ASSESSMENT OF ITS POTENTIAL RISKS [J].
GRAHAM, GD ;
BURMAN, KD .
ANNALS OF INTERNAL MEDICINE, 1986, 105 (06) :900-905
[14]  
GREEN M, 1961, BRIT MED J, V1, P210
[15]   CANCER RISKS IN THYROID-CANCER PATIENTS [J].
HALL, P ;
HOLM, LE ;
LUNDELL, G ;
BJELKENGREN, G ;
LARSSON, LG ;
LINDBERG, S ;
TENNVALL, J ;
WICKLUND, H ;
BOICE, JD .
BRITISH JOURNAL OF CANCER, 1991, 64 (01) :159-163
[16]   CANCER MORTALITY AFTER I-131 THERAPY FOR HYPERTHYROIDISM [J].
HALL, P ;
BERG, G ;
BJELKENGREN, G ;
BOICE, JD ;
ERICSSON, UB ;
HALLQUIST, A ;
LIDBERG, M ;
LUNDELL, G ;
TENNVALL, J ;
WIKLUND, K ;
HOLM, LE ;
LINDBERG, S ;
CEDERQUIST, E ;
WICKLUND, H ;
LARSSON, LG .
INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (06) :886-890
[17]   Thyroid cancer after diagnostic administration of iodine-131 [J].
Hall, P ;
Mattsson, A ;
Boice, JD .
RADIATION RESEARCH, 1996, 145 (01) :86-92
[18]  
HALNAN KE, 1983, BMJ-BRIT MED J, V287, P8121
[19]  
HANCOCK BW, 1977, CANCER, V39, P298, DOI 10.1002/1097-0142(197701)39:1<298::AID-CNCR2820390146>3.0.CO
[20]  
2-C